Clinical Trials Browser

Phase 2 × Endometrial Neoplasms × talazoparib × Clear all

NCT02912572 2025-07-10

Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer

Phase 2 Active not recruiting

106 enrolled 16 charts

Endometrial Neoplasms

NCT02127151 2021-08-06

PANDA

Phase 2 Withdrawn

Endometrial Neoplasms